Moderna
American biotechnology company
Positive
Negative
Entity sentiment
Reports
News
Opinions
Statements
Articles
Relations
science Jun 18, 2026, 10:35 PM
FDA panel endorses Moderna's mRNA flu shot for older adults - An FDA advisory panel recommended the approval of Moderna's mRNA flu vaccine for older adults after a trial showed it was 27% more effective than standard flu shots.
- The panel's endorsement includes a requirement for Moderna to conduct an additional clinical trial for older adults after the vaccine is available.
- The approval process remains uncertain due to the lack of permanent leadership at the FDA, which could affect the vaccine's availability this fall.
100
technology Jun 14, 2026, 9:00 AM
Moderna races to develop mRNA vaccine for Bundibugyo virus outbreak - Moderna is developing an mRNA vaccine for the Bundibugyo virus with support from CEPI.
- The Bundibugyo virus has caused fewer outbreaks than the original Ebola virus.
- Advancing the vaccine could improve future preparedness for Bundibugyo outbreaks.
100
science Jun 1, 2026, 4:30 PM
Ebola outbreak prompts urgent vaccine development by IAVI, Moderna, and Oxford - The Bundibugyo species of Ebola has caused nearly 250 deaths and over 1,000 suspected cases in the DR Congo.
- IAVI, Moderna, and the University of Oxford are developing vaccines specifically for this rare species.
- The development of these vaccines is crucial for controlling the outbreak and preparing for future epidemics.
200
science May 7, 2026, 8:51 PM
Moderna develops hantavirus mRNA vaccine amid rising concerns - Korea University and Moderna are working together on the early-stage development of a hantavirus mRNA vaccine focusing on Hemorrhagic Fever with Renal Syndrome.
- The collaboration addresses strains primarily found in East Asia and not in the U.S., where hantavirus infections are rare.
- Public trust in vaccine development could be undermined by claims of manipulation and profit motives, stemming from historical and current vaccine efforts.
100
science May 6, 2026, 11:00 PM
Moderna's mRNA flu vaccine surpasses standard shots in effectiveness - In a Phase 3 clinical trial, Moderna's mRNA flu vaccine outperformed standard flu shots with 27% increased protection.
- The trial involved over 40,000 adults across 301 sites in 11 countries, focusing on older populations at greater risk.
- The data from this trial may bolster chances for FDA approval and highlights the advantages of mRNA technology in rapid vaccine development.
100
science Feb 18, 2026, 3:55 PM
Moderna moves forward seeking FDA's approval for new flu vaccine after dispute - Moderna's new flu vaccine was initially blocked by the FDA due to a dispute over a clinical trial.
- The vaccine has shown increased effectiveness for adults aged 50 and older, but the trial excluded a recommended vaccine for those 65 and older.
- Moderna is now seeking full approval for certain age groups and hopes to launch the vaccine later this year.
100
science Feb 18, 2026, 2:52 PM
FDA agrees to review Moderna's flu vaccine after initial rejection - The FDA initially rejected Moderna's flu vaccine application but later agreed to review it following modifications.
- The review includes an application for full approval for adults aged 50-64 and accelerated approval for those aged 65 and older.
- Pending FDA approval, Moderna aims to offer the flu vaccine later this year to enhance protection for seniors against influenza.
100
science Feb 11, 2026, 11:37 PM
FDA rejects Moderna's flu vaccine application over trial design issues - The FDA denied Moderna's application due to concerns over clinical trial design that risked patient safety.
- Moderna used a flu vaccine not recommended by health authorities, raising allegations of trying to enhance its own product's efficacy.
- The incident reflects broader issues of trust and clarity in regulatory practices within the vaccine development industry.
100
science Feb 11, 2026, 12:15 AM
FDA refuses to consider moderna's mRNA flu vaccine application - Moderna received a refusal-to-file letter from the FDA regarding its new mRNA flu vaccine application.
- The FDA raised concerns about the conduct of Moderna's 40,000-person clinical trial, specifically its comparison to the standard of care.
- This refusal reflects heightened scrutiny of mRNA vaccines by the FDA under Health Secretary Robert F. Kennedy Jr.
100
science Feb 11, 2026, 12:01 AM
FDA rejects Moderna's flu vaccine application over comparison concerns - The FDA rejected Moderna's application due to issues with the trial comparator.
- Moderna argued that the stated concerns were inconsistent with previous FDA communications.
- The FDA's rejection highlights ongoing tensions around vaccine approvals and mRNA technology.
100
science Feb 10, 2026, 9:21 PM
FDA rejects Moderna's mRNA flu vaccine review amid controversies - The FDA declined to review a new flu vaccine developed by Moderna.
- Robert F. Kennedy Jr. has been a prominent figure in promoting skepticism towards vaccines.
- The decision reflects ongoing tensions between public health initiatives and anti-vaccine movements.
100
2026 All rights reserved
2026 All rights reserved